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Michael H. Malim wins the Retrovirology prize.
Retrovirology awards an annual Prize to recognize out-
standing achievements in the field by mid-career scien-
tists, older than 45 but younger than 60 [1]. The prize is
supported through a donation from the Ming K. Jeang
Foundation, an educational foundation based in Hous-
ton, Texas, USA. This year is the 6th edition of the
prize, alternating yearly between recognizing a non-HIV
retrovirologist and an HIV retrovirologist. Previous
Awardees are Steve Goff [2], Jo Sodroski [3], Karen
Beemon [4], Ben Berkhout [5] and Thierry Heidman [6]
and although we maintain strict confidentiality about
nominees who did not win, many of them were also
outstanding scientists who may well receive the prize in
the future, testament to how much the Retrovirology
Prize is truly valued by our community.
For 2010 the Editors have awarded the Retrovirology
Prize to Michael H. Malim (Figure 1). Mike is Professor
and Head of the Department of Infectious Diseases at
King’s College London, UK. He is a Fellow of the Acad-
emy of Medical Sciences, an EMBO member since 2005
and a Fellow of the Royal Society since 2007. Mike grad-
uated in Biochemistry from Bristol University (UK) and
obtained his DPhil from Oxford University working on
Ty retrotransposition. He then moved to the US at
Duke University, where he worked with Bryan Cullen as
a postdoctoral fellow and then, in 1992, set up his own
lab at the University of Pennsylvania. In 2001, he
returned to the UK at King’s College London. Amongst
his very many scientific achievements I would like to
highlight two. In the late’80s and early ‘90s Mike,
together with Bryan Cullen, showed that the HIV-1
accessory protein Rev was required for nuclear export of
unspliced viral RNA and that it acted by binding to a
highly structured RNA stretch called the Rev-response
element [7,8]. This represented a tremendous leap for-
ward in understanding HIV-1 biology. It also had
important implications outside the HIV field because at
the time not much was known about mRNA export
mechanisms and unspliced mRNA was not supposed to
be exported from the nucleus [9]. Thanks in part to
Mike’s contributions we then understood that HIV-1,
via Rev, evolved to recruit CRM1, a nuclear export
receptor, to bypass the normal cellular mRNA export
process and have its unspliced mRNA transported to
the cytoplasm for translation and packaging. A remark-
able exploitation of the cellular machinery!
In the mid ‘90s he turned his attention to another
HIV accessory protein called “viral infectivity factor” or
Vif. Several groups, including his own, had shown that
Vif-deficient HIV-1 could not replicate in certain cell
types, including peripheral blood mononuclear cells
(non-permissive cells) but could replicate in others (per-
missive cells). Despite substantial effort by several
groups, the function of Vif remained elusive for many
years. In 1998, Mike’s group using hybrids of permissive
and non-permissive cells showed that the non-permissive
phenotype was dominant and hence its activity very likely
depended on a host cell factor [10]. The quest for this
factor continued in Mike’s lab for several years, despite
the skepticism of colleagues. His efforts were eventually
vindicated in 2002 when Anne Sheehy in his group
reported that the factor being overcome by Vif was APO-
BEC3G, a single stranded DNA cytidine deaminase [11].
APOBEG3G was shown to hypermutate the viral genome
during reverse transcription and also to impair reverse
transcription itself and irreversibly damage the provirus
[12]. We then understood that Vif induced degradation
of APOBEC3G, preventing its incorporation into nascent
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viral particles. The discovery of the antiviral activity of
APOBEC changed our understanding of innate immunity
to retroviruses and retroelements in general.
As it is customary, I have asked Mike to share with us
some thoughts on his own work and on general issues
of interest to the community.
AF: When did you become interested in Science?
MHM: I suppose I always enjoyed science subjects at
high school. I particularly remember an inspiring chemis-
try teacher, who also used to teach us to play bridge. I
studied biochemistry as an undergraduate, and my
enthusiasm for research was ignited by a pretty unsuc-
cessful research project in fungal genetics. Nevertheless,
this persuaded me to pursue a PhD.
AF: Why did you decide to work on HIV-1?
MHM: It was during my post-graduate research in the
mid-1980s that HIV-1 was first isolated and charac-
terised. I recall being amazed by all the novel genes the
virus contained, and the unpredictable functions they
seemed to have. I decided to try and do post-doctoral
Figure 1 Prof. Michael Malim.
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research in the area, and have continued to work in that
area to this day - it has been an incredible experience!
AF: What do you consider your most important scien-
tific contributions?
MHM: Hmm... I think that two areas to which my (or
more accurately, our) research has contributed signifi-
cantly are in understanding the functions of the viral
Rev and Vif proteins. The work with Bryan on Rev and
RNA transport was an amazing time: in fact, when we
started in 1987, nuclear export was not really considered
to be a regulated process. The research on Vif leading to
the discovery of APOBEC3G, and its assignment as a
DNA mutator, was equally exciting: I still find it pretty
astonishing that one single protein can have such a pro-
found inhibitory effect on HIV infection.
AF: Is there any contribution of yours you feel has
been neglected?
MHM: No, not really, I feel the HIV literature gets
picked over pretty intensely, and so it is quite difficult for
an instructive paper to fly under the radar screen.
AF: Can you tell us about current research in your
laboratory?
MHM: We remain pretty focused on HIV-host interac-
tions. We continue to work on APOBEC3 proteins,
aspects of their anti-viral mechanism, their impact on
natural HIV infection, and potential effects on host cell
function. A second area of interest, which has brought us
back to RNA nuclear export, is how the history of viral
mRNA can influence the process of HIV particle
assembly - a project that was stimulated by trying to
understand post-integration blocks to HIV replication in
non-human cells. And, more recently, we have begun to
explore the mechanism(s) that cells use to register HIV
infection as well as the interplay between type 1 inter-
feron and HIV replication.
AF: Cross-disciplinary science is often praised but sel-
dom funded: do you have any advice for scientists who
want to bridge different fields?
MHM: I think this will become increasingly important
in biological and medical research; the advent of new
technologies and approaches drive fields forwards and
often depends on folks trained in disparate areas -
maths and physics to name just two that often crop up
in conversation. To promote meaningful interactions, I
think there are (at least) two key elements: good commu-
nication and pump-prime funding. My own biases are
that the former often proceed more productively through
personal contact, and the latter needs institutions and
funding agencies to think creatively about how they can
provide modest initial support for “blue skies” ideas.
AF: You have worked on both sides of the Atlantic:
what are the lessons that you learnt in the US and what
the ones that you learnt in the UK?
MHM: It can be pretty dangerous to make sweeping
generalisations about the idiosyncrasies of different
nations! However, I think the differences in science cul-
ture between the two countries are quite subtle these
days. I would venture that scientists in the US are less
constrained by the concerns of failure and have a bit
more of a “can do” attitude. For example, I think that
US labs are often happier to confront very ambitious
projects: though part of this is probably also due to the
longer amount of time that PhD students are allowed to
get their degrees. On the other hand, my own experience
has been that the UK seems a slightly easier place to col-
laborate... though I acknowledge this might be attributa-
ble to shifts in my own perspectives as time goes by!
AF: How important is mentorship to you?
MHM: I think that having people to turn to for advice
on important issues is essential, and I find there are
attributes to admire and aspire to in all sorts of people.
However, my belief is that mentoring works best on an
informal basis and that you need different folks for help
in different areas (you wouldn’t ask your butcher about
how to fix your second serve). Indeed, I think seeking and
providing counsel are central to building and supporting
a community - such as science and education. I am not
a great fan of formal mentorship schemes where you
have to rock up for your annual mentorship meeting
with someone you barely cross paths with, and who has
little clue about what you do (even if this does tick an
absurd box in the institutional procedure manual). So, I
am always happy to provide advice to junior/senior col-
leagues on almost anything, but hope that they balance
my views with those of others.
AF: What do you most value in your colleagues?
MHM: Among both institutional and fellow scientists, I
suppose I value a commitment to the broader of commu-
nity - we are not working in isolation, and co-operation
and collegiality, even when in competition, are vital. For
scientists, I certainly admire those with creativity and
dedication, blended with a healthy sense of irreverence.
AF: The Retrovirology prize is awarded to “mid
career” scientists: what do you think are the specific
challenges facing this group of colleagues?
MHM: These are different for all of us! I am a strong
believer that we are only as good as our last paper, and
that we therefore need to continue to strive for impact,
innovation and quality. I think this is what gets us out
of bed in the morning, and will enable us to contribute
in the face of all the talent that is out there. For me, per-
sonally, a major challenge is balancing the demands of
running a mid-size research group with burgeoning
administrative and institutional roles and responsibil-
ities. The latter can be very rewarding, especially as one
sees new programmes and initiatives develop, and is cer-
tainly of great importance to the future success of
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respective institutions, but it can be consuming at times:
I think compartmentalisation has to be the key.
AF: You are Editor of several journals, including one
open-access. What is your experience as an Editor and
what do you think are the most significant changes that
open-access publication brought about?
MHM: As you know yourself, editing can be very
rewarding, especially when you have the opportunity to
shape the future of a journal. I was one of the initial
Editors of PLoS Pathogens (2005), and I am chuffed with
the success of this journal. It has certainly filled an
important niche that did not exist previously in patho-
gen-related research. Working with the crop of volunteer
Editors we have had for HIV/AIDS has been a privilege.
Beyond the content of this particular journal, I am a
great supporter of open-access publishing. The idea that
anyone, anywhere can read about, and benefit from, the
science that is being sponsored by public funds seems
fundamental to the scientific ethos. It is gratifying that so
many researchers have embraced this notion and send so
much of their better work to open-access journals.
AF: Students in the near future, at least in the UK,
will leave university with a substantial debt burden.
Those who embark in a career in science will struggle
for many years on low paid jobs and insecurity about
future prospects. Can you give them good reasons why
they should go into science?
MHM: Correct, these are certainly testing times. But,
funding has dipped before, and such matters are cyclical
so I remain optimistic that they will recover. As for
embarking upon research as a career, it has so much to
recommend it. It is never dull: it is hard to match the
challenge and buzz of discovery and learning, the con-
stant renewal of lab personnel with new perspectives and
ideas is always invigorating, and teaching/training can
be incredibly rewarding. While the hours can be long,
they are also very flexible, and I think this makes it a
career with excellent compatibility with family life. I
have also been fortunate to make many lifetime friends
from all over the world, and conferences always provide
good venues to put one’s efforts into broader perspective,
catch up, and, perhaps, even raise a glass or two!
AF: Who would you like to thank?
MHM: Several sets of people: the labs I have trained
in, the institutions and funders who have supported me,
various colleagues, and the wonderful trainees, fellows
and staff who have worked in my lab. And, of course, my
family for their continuing tolerance.
Received: 17 November 2010 Accepted: 1 December 2010
Published: 1 December 2010
References
1. Jeang KT: Life after 45 and before 60: the Retrovirology Prize.
Retrovirology 2005, 2:26.
2. Jeang KT: Small philanthropy and big science: the RETROVIROLOGY prize
and Stephen P. Goff. Retrovirology 2005, 2:43.
3. Lever AM: Science–a life fully lived: Joe Sodroski wins the 2006
Retrovirology Prize. Retrovirology 2006, 3:45.
4. Boris-Lawrie K: Bridging fundamental RNA biology, retroviral replication,
and oncogenesis: Karen Beemon wins the 2007 Retrovirology Prize.
Retrovirology 2007, 4:88.
5. Jeang KT: The 2008 Retrovirology Prize: Ben Berkhout and his RNA
world. Retrovirology 2008, 5:113.
6. Saib A, Benkirane M: Endogenous retroviruses: Thierry Heidmann wins
the 2009 Retrovirology prize. Retrovirology 2009, 6:108.
7. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR: The HIV-1 rev trans-
activator acts through a structured target sequence to activate nuclear
export of unspliced viral mRNA. Nature 1989, 338:254-257.
8. Malim MH, Tiley LS, McCarn DF, Rusche JR, Hauber J, Cullen BR: HIV-1
structural gene expression requires binding of the Rev trans-activator to
its RNA target sequence. Cell 1990, 60:675-683.
9. Malim MH, Cullen BR: Rev and the fate of pre-mRNA in the nucleus:
implications for the regulation of RNA processing in eukaryotes. Mol Cell
Biol 1993, 13:6180-6189.
10. Simon JH, Gaddis NC, Fouchier RA, Malim MH: Evidence for a newly
discovered cellular anti-HIV-1 phenotype. Nat Med 1998, 4:1397-1400.
11. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene
that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
Nature 2002, 418:646-650.
12. Malim MH: APOBEC proteins and intrinsic resistance to HIV-1 infection.
Philos Trans R Soc Lond B Biol Sci 2009, 364:675-687.
doi:10.1186/1742-4690-7-103
Cite this article as: Fassati: From Duke to King’s: Michael Malim wins
the 2010 Retrovirology prize. Retrovirology 2010 7:103.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fassati Retrovirology 2010, 7:103
http://www.retrovirology.com/content/7/1/103
Page 4 of 4
